ticker nerd logo
Viking Therapeutics Inc

Viking Therapeutics Inc Stock Forecast & Price Prediction

Live Viking Therapeutics Inc Stock (VKTX) Price
$51.71

9

Ratings

  • Buy 9
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$51.71

P/E Ratio

-59.51

Volume Traded Today

$2.3M

Dividend

Dividends not available for VKTX

52 Week High/low

99.41/8.28

Viking Therapeutics Inc Market Cap

$5.56B

🛑 Alert: These ten stocks could have higher potential than $VKTX 🛑

Before you buy VKTX you’ll want to see this list of ten stocks that have huge potential. Want to see if VKTX made the cut? Enter your email below

VKTX Summary

Based on ratings from 9 stock analysts, the Viking Therapeutics Inc stock price is expected to increase by 119.38% in 12 months. This is calculated by using the average 12-month stock price forecast for Viking Therapeutics Inc. The lowest target is $90.00 and the highest is $138.00. Please note analyst price targets are not guaranteed and could be missed completely.

VKTX Analyst Ratings

Viking Therapeutics Inc has a total of 9 Wall St Analyst ratings. There are 9 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Viking Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

VKTX stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

roger song
Jefferies

Buy

$110.0

rated

Jul 3, 2024
justin zelin
BTIG

Buy

$125.0

reiterated

Jul 3, 2024
annabel samimy
Stifel Nicolaus

Buy

$95.0

maintained

Jul 1, 2024
michael ulz
Morgan Stanley

Buy

$105.0

initiatedcoverage

Jun 27, 2024
joseph pantginis
H.C. Wainwright

Buy

$90.0

reiterated

Jun 24, 2024
jay olson
Oppenheimer

Buy

$138.0

maintained

Jun 24, 2024
naz rahman
Maxim Group

Buy

$120.0

maintained

Jun 4, 2024
thomas smith
Leerink Partners

Buy

$118.0

maintained

Jun 4, 2024
steven seedhouse
Raymond James

Buy

None

maintained

Jun 2, 2024
joon lee
Truist Financial

Buy

$120.0

maintained

May 16, 2024
dylan dupuis
Roth MKM

Buy

$32.0

reiterated

Aug 8, 2023
yale jen
Laidlaw

Buy

$35.0

maintained

May 16, 2023
scott henry
Roth MKM

Buy

$24.0

maintained

May 3, 2023
matt koranda
Roth MKM

Buy

$19.0

maintained

Mar 29, 2023
anthony vendetti
Maxim Group

Buy

$25.0

rated

Mar 28, 2023
andy hsieh
William Blair

Buy

None

reiterated

Jan 9, 2023
matthew luchini
BMO Capital

Buy

$15.0

reiterated

Nov 4, 2021
mayank mamtani
B.Riley Financial

Hold

None

rated

Aug 6, 2021
jason mccarthy
Maxim Group

Buy

$14.0

initiatedcoverage

Jul 29, 2021
derek archila
Wells Fargo

Buy

$13.0

reiterated

Apr 28, 2021

VKTX Company Information

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX
Viking Therapeutics Inc (VKTX)

When did it IPO

2015

Staff Count

28

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Brian Lian Ph.D.

Market Cap

$5.56B

Viking Therapeutics Inc (VKTX) Financial Data

In 2023, VKTX generated $0 in revenue, which was a decrease of nan% from the previous year. This can be seen as a signal that VKTX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

nan %
From Previous Year

Revenue From 2022

$0

nan %
From Previous Year

Revenue From 2023

$0

nan %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -12.8%
  • Return on equity TTM -17.6%
  • Profit Margin 0.0%
  • Book Value Per Share 8.47%
  • Market capitalisation $5.56B
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-0.92
... ...

Similar Stocks to Viking Therapeutics Inc - VKTX

🛑 Alert: These ten stocks could have higher potential than $VKTX 🛑

Before you buy VKTX you’ll want to see this list of ten stocks that have huge potential. Want to see if VKTX made the cut? Enter your email below

...

VKTX Frequently asked questions

The highest forecasted price for VKTX is $138.00 from jay olson at Oppenheimer.

The lowest forecasted price for VKTX is $90.00 from joseph pantginis from H.C. Wainwright

The VKTX analyst ratings consensus are 9 buy ratings, 0 hold ratings, and 0 sell ratings.